FORA Capital LLC Sells 17,711 Shares of Astera Labs, Inc. $ALAB

FORA Capital LLC reduced its stake in Astera Labs, Inc. (NASDAQ:ALAB) by 39.0% in the second quarter, HoldingsChannel reports. The institutional investor owned 27,722 shares of the company’s stock after selling 17,711 shares during the quarter. FORA Capital LLC’s holdings in Astera Labs were worth $2,507,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the stock. Oliver Lagore Vanvalin Investment Group bought a new stake in shares of Astera Labs in the 2nd quarter worth $29,000. Bernard Wealth Management Corp. bought a new position in shares of Astera Labs during the second quarter valued at about $36,000. Clearstead Trust LLC boosted its holdings in Astera Labs by 46,100.0% during the second quarter. Clearstead Trust LLC now owns 462 shares of the company’s stock worth $42,000 after purchasing an additional 461 shares during the last quarter. Advisors Asset Management Inc. grew its position in Astera Labs by 68.6% in the 2nd quarter. Advisors Asset Management Inc. now owns 477 shares of the company’s stock worth $43,000 after purchasing an additional 194 shares in the last quarter. Finally, Manchester Capital Management LLC grew its position in Astera Labs by 141.5% in the 2nd quarter. Manchester Capital Management LLC now owns 483 shares of the company’s stock worth $44,000 after purchasing an additional 283 shares in the last quarter. 60.47% of the stock is currently owned by institutional investors.

Astera Labs Price Performance

NASDAQ:ALAB opened at $148.85 on Friday. The company has a market capitalization of $25.14 billion, a P/E ratio of 134.10, a P/E/G ratio of 2.77 and a beta of 1.51. The business has a fifty day simple moving average of $166.62 and a two-hundred day simple moving average of $153.61. Astera Labs, Inc. has a 1 year low of $47.13 and a 1 year high of $262.90.

Astera Labs (NASDAQ:ALAB) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of $0.39 by $0.10. Astera Labs had a return on equity of 13.48% and a net margin of 27.50%.The firm had revenue of $230.58 million for the quarter, compared to analysts’ expectations of $206.42 million. During the same quarter in the prior year, the firm earned $0.23 EPS. The business’s revenue for the quarter was up 103.9% compared to the same quarter last year. Astera Labs has set its Q4 2025 guidance at 0.50-0.510 EPS. As a group, analysts anticipate that Astera Labs, Inc. will post 0.34 earnings per share for the current year.

Insider Buying and Selling at Astera Labs

In other Astera Labs news, CFO Michael Truett Tate sold 11,430 shares of the stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $144.69, for a total transaction of $1,653,806.70. Following the completion of the transaction, the chief financial officer owned 192,297 shares in the company, valued at $27,823,452.93. This trade represents a 5.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Manuel Alba sold 150,000 shares of Astera Labs stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $166.18, for a total transaction of $24,927,000.00. Following the completion of the transaction, the director owned 1,574,498 shares of the company’s stock, valued at $261,650,077.64. The trade was a 8.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 586,936 shares of company stock valued at $89,331,140. Insiders own 12.50% of the company’s stock.

Analysts Set New Price Targets

ALAB has been the topic of several recent analyst reports. Roth Capital lifted their target price on shares of Astera Labs from $200.00 to $225.00 and gave the stock a “buy” rating in a research report on Wednesday, November 5th. Citigroup reiterated an “outperform” rating on shares of Astera Labs in a report on Tuesday. Morgan Stanley restated an “overweight” rating and issued a $210.00 price objective on shares of Astera Labs in a research note on Wednesday, December 3rd. BNP Paribas Exane initiated coverage on Astera Labs in a research report on Thursday, November 20th. They set an “outperform” rating and a $225.00 target price for the company. Finally, Northland Capmk raised shares of Astera Labs from a “hold” rating to a “strong-buy” rating in a report on Monday, November 17th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat.com, Astera Labs has a consensus rating of “Moderate Buy” and an average target price of $188.17.

Astera Labs Profile

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.